Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 15, 2021

Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
J. Clin. Oncol 2021 Oct 01;39(28)3109-3117, AJ Moskowitz, G Shah, H Schöder, N Ganesan, E Drill, H Hancock, T Davey, L Perez, S Ryu, S Sohail, A Santarosa, N Galasso, R Neuman, B Liotta, W Blouin, A Kumar, O Lahoud, CL Batlevi, P Hamlin, DJ Straus, I Rodriguez-Rivera, C Owens, P Caron, AM Intlekofer, A Hamilton, SM Horwitz, L Falchi, E Joffe, W Johnson, C Lee, ML Palomba, A Noy, MJ Matasar, G Pongas, G Salles, S Vardhana, BW Sanin, G von Keudell, J Yahalom, A Dogan, AD Zelenetz, CH Moskowitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading